RSNA 2021 Women's Imaging Preview

DBT continues to show promise a decade after commercial availability

By Amerigo Allegretto, staff writer

Sunday, November 28 | 10:30 a.m.-11:30 a.m. | SSBR01-2 | Room TBA
Presenters will give the verdict on whether digital breast tomosynthesis (DBT) has been a successful screening method since the first commercially available system was released in 2011.

Dr. Liane Philpotts from Yale University will present the findings from a study that she and a team of researchers conducted assessing screening mammography metrics over the past decade since adopting DBT. Over 207,000 DBT mammograms were included in the study. The researchers looked at factors such as recall rates, cancer detection rates, and false-negative rates.

They found that DBT's recall rate averaged 7.5%, cancer detection rates averaged 5.4, and the false-negative rate averaged 0.8 per 1,000. For women with nondense breast tissue, the recall rate averaged 6.8% and the cancer detection rate was 5.3. For women with dense breast tissue, the recall rate averaged 8% and the cancer detection rate was 5.1.

Find out what Philpotts et al have to say about these results in their presentation.